FATE vs PATH
Fate Therapeutics Inc (FATE) versus Uipath Inc (PATH) — a side-by-side from cached financials, not a winner call.
Fate Therapeutics Inc (FATE) is a biotechnology company listed on US.
Uipath Inc (PATH) is a software - infrastructure company listed on US.
Latest reported FATE revenue for 2024-12-31 was $13.6M. Net income was -$186.3M. Revenue was down 78.5% from 2023-12-31 to 2024-12-31. FATE currently screens at market cap $331.0M.
Latest reported PATH revenue for 2026-01-31 was $1.61B. Net income was $282.3M. Revenue was up 12.7% from 2025-01-31 to 2026-01-31. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
FATE currently screens at market cap $331.0M. PATH currently screens at market cap $6.07B and trailing P/E 19.4.
Not investment advice. Open the FATE and PATH stock pages for the full models.
Not investment advice.